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Matrix metalloproteinases (MMPs), in particular the gelatinases (MMP-2 and -9), play a significant role in tumour invasion and
angiogenesis. The expression and activities of MMPs have not been characterised in malignant mesothelioma (MM) tumour samples.
In a prospective study, gelatinase activity was evaluated in homogenised supernatants of snap frozen MM (n¼35), inflamed pleura (IP,
n¼12) and uninflammed pleura (UP, n¼14) tissue specimens by semiquantitative gelatin zymography. Matrix metalloproteinases
were correlated with clinicopathological factors and with survival using Kaplan–Meier and Cox proportional hazard models. In MM,
pro- and active MMP-2 levels were significantly greater than for MMP-9 (P¼0.006, Po0.001). Active MMP-2 was significantly greater
in MM than in UP (P¼0.04). MMP-2 activity was equivalent between IP and MM, but both pro- and active MMP-9 activities were
greater in IP (P¼0.02, P¼0.009). While there were trends towards poor survival with increasing total and pro-MMP-2 activity
(P¼0.08) in univariate analysis, they were both independent poor prognostic factors in multivariate analysis in conjunction with
weight loss (pro-MMP-2 P¼0.03, total MMP-2 P¼0.04). Total and pro-MMP-2 also contributed to the Cancer and Leukemia Group
B prognostic groups. MMP-9 activities were not prognostic. Matrix metalloproteinases, and in particular MMP-2, the most abundant
gelatinase, may play an important role in MM tumour growth and metastasis. Agents that reduce MMP synthesis and/or activity may
have a role to play in the management of MM.
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Malignant mesothelioma (MM) is an aggressive and invariably
fatal serosal tumour of increasing incidence usually associated with
asbestos exposure. Median survival in the UK is less than 6 months
from the date of diagnosis (Edwards et al, 2000). Malignant
mesothelioma is characterised by rapid progression and invasion
of intrathoracic structures. Although commonly perceived as a
tumour that rarely metastasises, nodal disease is present in about
40% of patients undergoing extrapleural pneumonectomy (Sugar-
baker and Norberto, 1998), while distant metastases are seen in at
least 70% at the time of death (Rusch et al, 1991). Malignant
mesothelioma responds poorly to conventional modes of therapy
including surgery, chemotherapy and radiotherapy (Sterman et al,
1999). Staging by the conventional criteria of Tumour–Nodes–
Metastasis (TNM) is difficult in MM: that proposed by the
International Mesothelioma Interest Group (IMIG) is the most
recent TNM staging system (Rusch, 1995). However, in a large
series of patients managed by radical surgery and chemora-
diotherapy, this staging system failed to stratify survival (Sugar-
baker et al, 1999). For MM, prognostic scoring systems
incorporating clinicopathological variables have been proposed
by the European Organisation for Research and Treatment of
Cancer (EORTC) (Curran et al, 1998) and the Cancer and
Leukemia Group B (CALGB) (Herndon et al, 1998). These systems
have been useful in predicting survival in our patient population
(Edwards et al, 2000).
Novel prognostic factors, such as microvessel density (MVD), a
marker of the intensity of angiogenesis, have been examined in
MM. High MVD is associated with a poor outcome in this disease
(Kumar-Singh et al, 1997; Edwards et al, 2001), in keeping with the
results from similar studies in other solid tumours (Dickinson et al,
1994; Fox et al, 1994; Cox et al, 2000c). Furthermore, in other solid
tumours, such as nonsmall cell lung cancer, novel biological
staging systems are being developed, which contribute indepen-
dently to TNM stage (Cox et al, 2000a; O’Byrne et al, 2001).
Proteolysis of the extracellular matrix and basement membrane,
by proteases such as matrix metalloproteinases (MMPs), is a
central part of tumour growth and metastasis. The stromal
remodelling mediated by these enzymes also facilitates tumour
angiogenesis. MMPs are a family of zinc-dependent enzymes,
which are implicated in the growth of primary and secondary
tumours (Cox et al, 1999). Overexpression of MMPs, in particular
gelatinase A (MMP-2), gelatinase B (MMP-9) and stromelysin-3
(MMP-11), is related to tumour progression and metastasis in
solid tumours including gastric (Schwartz, 1996), colon (Karakiu-
lakis et al, 1997) and lung cancer (Cox et al, 2000b).
Reports using semiquantitative gelatin zymography have
correlated MMP-2 and/or MMP-9 activity with survival and
disease progression in several solid tumour types (Brown et al, Received 6 September 2002; revised 17 February 2003; accepted 26
February 2003
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2000; Lengyel et al, 2001; Di Nezza et al, 2002; Waas et al, 2002).
The use of SDS in the buffers activates latent gelatinase isoforms,
which enables assessment of both the latent (pro) and active bands
of enzymatic activity. Although MMP expression has been
described in MM cell lines (Harvey et al, 2000; Liu et al, 2001),
the activity of MMPs has not been described in MM tumour
samples. We have assessed, by gelatin zymography, the activities of
MMP-2 and -9 in specimens of benign pleura and MM.
MATERIALS AND METHODS
Patients and samples
Patients referred to the regional Department of Cardiothoracic
Surgery for surgical management of pleural diseases were
identified prospectively. Patients were due to undergo surgery
for biopsy, management of pleural effusion, empyema or
pneumothorax or for palliative or radical surgery for malignant
mesothelioma. Clinicopathological prognostic factors, including
CALGB (Herndon et al, 1998) and EORTC (Curran et al, 1998)
prognostic groups were recorded before surgery, as described
previously (Edwards et al, 2000). For the patients undergoing
radical surgery, the IMIG TNM pathological stage was derived.
Samples of MM, inflamed pleura (IP) or uninflammed, benign
pleura (UP) were collected at surgery from consecutive patients.
Surgery in MM patients (n¼35, 23 epithelioid, seven mixed
cellularity, five sarcomatoid) was performed either for diagnostic
biopsy or for symptom control. IP patients (n¼12) had empyema
thoracis and underwent decortication of visceral pleura and/or
parietal pleurectomy. UP specimens were taken from patients
(n¼15) at the time of pleurectomy for primary spontaneous
pneumothorax. Samples were assessed macroscopically and
representative areas (e.g. tumour nodules) were processed as
formalin-fixed, paraffin-embedded blocks for diagnostic evalua-
tion, or snap frozen in liquid nitrogen and stored at  801C for
zymography. Standard diagnostic immunohistochemistry was
performed to confirm the diagnosis, using antibodies including
CEA, BerEP4, AUA-1 and HBME1, where appropriate. Following
surgery, the detailed histopathological report and diagnostic slides
were reviewed by a second pathologist to confirm the diagnosis.
Gelatin zymography
Samples were homogenised mechanically at 41C in a zymography
homogenisation buffer (containing the protease inhibitor phenyl-
methylsulphonyl fluoride (PMSF, Sigma-Aldrich, Poole, UK, at
0.1mM), centrifuged and the supernatant refrozen. Protein
concentrations were derived with a Bradford assay. Wells of a
gelatin preimpregnated SDS–polyacrylamide gel (Novex, Frank-
furt, Germany) were loaded with samples (3.75mg protein) and run
for 100min at 125mV in Tris-glycine SDS running buffer (Novex
Frankfurt, Germany), during which time the bromophenol blue
front reached the bottom of the gel. Positive controls included the
Type I Collagenases AG770 (Chemicon International, Harrow, UK)
and C-0130 (Sigma-Aldrich); the molecular weight marker SeeBlue
Pre-Stained Standards (Novex) was also used. Gels were renatured
in zymogram renaturing buffer (Novex) for 45min and incubated
overnight at 371C in zymogram developing buffer (Novex). After
staining with 0.5% Coomassie Blue G-250, destaining with 30%
methanol, 10% acetic acid solution revealed clear bands of
gelatinolytic activity. Within each assay, all samples were assessed
simultaneously using the same reagents and batch of gels. Gels
were digitally photographed and band densitometry assessed using
a computer image analysis system (Scion Image, Frederick,
Maryland, USA), to give a semiquantitative assay of enzymatic
activity. Densitometry of each band was assessed blind to the
diagnostic group three times and the mean score used for
statistical analysis. The semiquantitative nature of this protocol
was validated by densitometric analysis of serial dilutions of the
two samples with the strongest bands. Assays were repeated for all
samples and the results obtained for different runs were correlated.
Three samples were run in each gel as internal positive controls.
All gels were run under identical conditions with the same batch of
reagents and densitometry results standardised between gels.
Statistics
Gelatin zymography was performed and results analysed prospec-
tively. Statistical analysis was performed using the SPSS software
system (SPSS for Windows Version 9.0, SPSS Inc., Chicago, USA).
Differences in densitometry readings between groups were
assessed with the Mann–Whitney U and Kruskal–Wallis tests,
where appropriate. Cancer-specific survival curves were estimated
using the Kaplan–Meier method and the log-rank test was used to
assess the statistical significance of differences between groups. A
Cox proportional hazards regression model (Cox, 1972) was used
to identify the impact of prognostic factors on survival and
estimate hazard ratios and 95% confidence intervals (CIs). The
assumption of proportional hazards was assessed graphically by
plotting log[ log(survivor)] against log(time) for each group.
Prognostic variables identified by univariate analysis, with Po0.1,
were analysed in multivariate Cox models. A forward, stepwise
selection procedure was used, with variables being added to the
model according to a partial likelihood ratio test, using an entry
criterion of Po0.05.
RESULTS
Patients
Overall median survival in the MM group was 7.5 months. Six
months and 1 year survival rates were 66 and 34% respectively.
The definitive surgical procedures performed were radical surgery
in 14 patients (11 extrapleural pneumonectomies and three radical
decortications), palliative debulking surgery (Martin-Ucar et al,
2001) in 16 and biopsy alone in five patients. Although patients
who underwent radical surgery survived longer than those who did
not (P¼0.04, log rank), the surgical procedure performed was not
an independent factor in subsequent multivariate analyses.
Three patients (8.6%) died within 30 days of surgical biopsy.
Two patients developed postoperative respiratory failure and died
on days 11 and 23, while a third suffered a cardiac arrest following
an acute intrathoracic haemorrhage on day 10. These three
patients were excluded from subsequent survival analyses.
Gelatin zymography
Methods validation Serial dilution of the two strongest MM
samples (between 1 and 30mg) demonstrated that at protein loads
of greater than 10mg per well, the densitometry values reached a
plateau (data not shown). The relation of protein load to
densitometry value was linear up to and including 10mg protein
per well, which was that used in the main experiments. When
samples were run on different days and the correlation between
them assessed, correlation coefficients of 0.936, 0.863, 0.973 and
0.946 were obtained for pro-, active MMP-9, pro- and active MMP-
2 bands, respectively (Po0.0001). The variation between gels of
the control samples was minimal (data not shown).
Gelatin zymography results
Initially, 22 MM samples were compared with the UP and IP
specimens. Densitometry readings for each group and Mann–
Whitney P values are shown in Table 1. Subsequently, the gelatin
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alone. The latter group was used to examine correlations with
clinicopathological factors and survival.
Gelatinolytic bands corresponding to pro-MMP-9 and pro- and
active MMP-2 were seen in all 35 cases of MM. No detectable active
MMP-9 was seen in nine of the 35 MM cases (26%). MMP-2 was
the predominant gelatinase seen in MM (Figure 1). Among the 35
MM cases, pro-MMP-2 and -9 levels were mean 2600 (95% CI
2130–3070) and 1640 (960–2330) respectively (P¼0.006). Values
were 1540 (1300–1770) and 850 (580–1110) for the active isoforms
(Po0.001). It was possible to determine densitometry values for all
gelatinase isoforms in each of the UP and IP cases (Table 1).
Correlation with clinicopathological variables
Active MMP-2 was significantly elevated in MM compared with UP
specimens (P¼0.04, Table 1, Figure 2). There were no differences
between MM and UP groups with regard to MMP-9 activity. There
was significantly greater pro- and active MMP-9 gelatinolytic
activity in IP specimens compared to the UP (P¼0.05, 0.01
respectively) and MM (P¼0.02, 0.009 respectively) groups. There
was no significant difference in pro- and active MMP-2
gelatinolytic activity between IP and either MM or UP specimens.
Preoperative white cell count was associated with greater total
MMP-9 (sum of pro- and active MMP-9, P¼0.0006) and a trend
towards a similar result was seen with thrombocytosis (P¼0.06).
There were no significant correlations between gelatinases and
gender, age, presence of chest pain or weight loss, cell type or
performance status. There was no correlation between any MMP
isoform and either the EORTC or CALGB prognostic scores.
Pathological staging was performed only for the 13 patients who
underwent radical surgery. Nodal stage was N0 in seven, N1 in one
and N2 in five patients. Pro-, active and total MMP-2 activities
were greater in those with extrapleural nodal metastasis than
without (Table 2). There were no associations seen between
gelatinases and pathological T or overall IMIG TNM stages.
Correlation with survival
In univariate Cox proportional hazards analysis, trends towards
increasing pro- and total MMP-2 activities (as continuous
variables) and poor prognosis were seen (P¼0.08, HR 1.0003,
95% CI 1.0000–1.0006 and P¼0.08, HR 1.0002, 95% CI 1.0000–
1.0005 respectively, Figure 3). However, although trends towards
poor prognosis were seen with the categorical analyses, these did
not reach statistical significance in either univariate Cox propor-
tional hazards models (P¼0.16 and 0.19 respectively) or the log-
rank test (P¼0.15 and 0.19). There was no significant relation
between poor prognosis and active MMP-2, or total, pro-, or active
MMP-9. Similarly, the ratio of pro- to active MMP-2 or -9
(activation ratio) and total gelatinolytic activity (sum of all four
isoforms) were not prognostic.
Table 1 Zymogram densitometry values in MM and benign pleura
n Pro-MMP-9 Active MMP-9 Pro-MMP-2 Active MMP-2
MM 22 1996 1400 2743 1936
(1268–2724) (953–1848) (2102–3385) (1183–2689)
UP 15 1934 1423 2297 1038
(1466–2403) (1063–1783) (1543–3051) (648–1428)
IP 14 3642 2380 3485 2499
(2324–4960) (1591–3170) (2132–4837) (1005–3994)
Mann–Whitney P values:
MM vs UP 0.5 0.6 0.4 0.04
IP vs MM 0.02 0.009 0.7 0.7
IP vs UP 0.05 0.01 0.1 0.07
Data are displayed as mean arbitrary densitometry units (95% CI). MM¼malignant mesothelioma; UP¼uninflammed pleura; IP¼inflammed pleura; MMP-9¼gelatinase B;
MMP-2¼gelatinase A.
PC  MM  IP MM IP UP         UP      MM       MM        IP          IP          MM
Pro-MMP-9 (92 kDa) 
Active MMP-9 (82 kDa)
Pro-MMP-2 (72 kDa) 
Active MMP-2 (62 kDa)
Figure 1 Gelatin zymogram of malignant mesothelioma (MM), inflamed pleura (IP) and uninflamed pleura (UP). Snap-frozen samples were homogenised
and the supernatant proteins resolved in a gelatin preimpregnated polyacrylamide gel. Gels were developed to show clear bands of gelatinolysis, correlating
with the latent, pro- and active isoforms of MMP-2 and -9.
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In addition to the association between the operation performed
and survival (as outlined above), clinicopathological factors
significant in univariate survival analysis were weight loss 45%
(P¼0.0006), nonepithelioid cell type (P¼0.0049) and preopera-
tive haemoglobin o14gdl
 1 (P¼0.03). These were entered with
either pro-MMP-2 or total MMP-2 gelatinolytic activity into Cox
proportional hazards multivariate models. Both pro-MMP-2
(P¼0.03) and total MMP-2 (P¼0.04) were independent prog-
nostic factors in conjunction with weight loss (P¼0.0008),
whereas the other factors entered were not. Similarly, high pro-
MMP-2 (P¼0.04) and total MMP-2 (P¼0.04) contributed
independently to the CALGB prognostic scoring system
(P¼0.005 and 0.02 respectively). The EORTC risk groups were
not prognostic in univariate analysis in this series (P¼0.16, log
rank) and therefore were not tested in multivariate analysis.
DISCUSSION
Malignant mesothelioma is characterised by extensive local growth
and invasion of intrathoracic organs. This pattern of tumour
development suggests an important role for proteases, including
the MMPs, in the evolution of the disease. This study demonstrates
the consistent expression of active and latent forms of MMP-9 and
particularly MMP-2 in MM tumour samples by gelatin zymogra-
phy. We used whole tumour extracts rather than microdissected
extracts since recent evidence has suggested that stromal expres-
sion of MMPs is important in tumour progression (Himelstein
et al, 1994; Nawrocki et al, 1997; Polette and Birembaut, 1998;
DeClerck, 2000; Kikuchi et al, 2000). Gelatin zymography was
found to be reproducible, with a low variation between samples
run on different days and between the control samples run in each
gel. The serial dilution experiment confirmed the semiquantitative
nature of the assay when 10mg protein was loaded to each well.
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Figure 2 Boxplots showing the differences in MMP activity between MM (n¼22), UP (n¼12) and IP (n¼15). Data are shown for pro-MMP-9 (A),
active MMP-9 (B), pro-MMP-2 (C) and active MMP-2 (D). Horizontal bars represent the median values, boxes the interquartile range, vertical bars the 10–
90% range and solid circles the outliers. MMP enzyme activity was measured with semiquantitative gelatin zymography and is expressed by arbitrary
densitometry units per milligram protein.
MMPs in mesothelioma
JG Edwards et al
1556
British Journal of Cancer (2003) 88(10), 1553–1559 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yThe benign UP control group specimens were obtained from
patients undergoing pleurectomy for primary spontaneous pneu-
mothorax. However, even this group may not display true baseline
expression of MMPs. Both acute and chronic inflammatory
changes were noted in the histopathology reports of the diagnostic
tissue blocks from the ‘UP’ specimens that accompanied the snap-
frozen samples used in this study. It is possible to speculate,
therefore, that we have underestimated the degree of upregulation
of MMPs in MM, and indeed in IP, compared to UP.
The patterns of gelatinolytic activity seen in MM, IP and UP are
likely to reflect both the nature and extent of the inflammatory cell
infiltrate in these conditions, and between benign and malignant
mesothelial cells. The predominant gelatinase expressed by
macrophages and neutrophils in inflammatory conditions such
as emphysema, asthma, sepsis and inflammatory bowel disease is
MMP-9 (Finlay et al, 1997; Mautino et al, 1997; Pugin et al, 1999),
which is in keeping with the significantly elevated activity of this
enzyme seen in IP specimens compared to either MM or UP
samples. Furthermore, the observation that total MMP-9 was
significantly greater in MM patients with a WCC greater than
8.3 10
9l
 1 supports this contention. The levels of active MMP-2
were found in this study to be significantly higher in MM than UP.
This finding suggests that the MMP-2 activity seen in MM may be
more specific than MMP-9 to the carcinogenic process.
Activities of MMP-2 and -9 isoforms have been investigated
by gelatin zymography in other solid tumours. Upregulation of
MMP-2 is seen in solid tumours including hepatocellular (Maatta
et al, 2000), colorectal (Liabakk et al, 1996; Baker et al, 2000; Waas
et al, 2002) and ovarian cancers (Lengyel et al, 2001). With regard
to the relation of MMP activity, as assessed by gelatin zymography,
with prognosis, results differ between studies and tumour types. In
oral squamous cell carcinoma, activities of MMP-2 and -9 correlate
Table 2 Correlation between MMP-2 and MMP-9 activities and clinicopathological variables
Variable n Pro-MMP-9
Active
MMP-9
Total
MMP-9 Pro-MMP-2
Active
MMP-2
Total
MMP-2
Cell type Epithelioid 23 1176 608 1693 2104 1199 3418
Nonepithelioid 12 816 633 1419 2422 1491 4087
P 0.082 0.344 0.237 0.281 0.889 0.314
White blood cells o8.3 10
9l
 1 13 788 511 1279 1988 1193 3426
X8.3 10
9l
 1 22 1167 638 1796 2468 1559 3895
P 0.065 0.109 0.006 0.585 0.824 0.539
Platelets o400 10
9l
 1 22 824 582 1419 2279 1449 3547
X400 10
9l
 1 13 1176 608 1917 2105 1199 3771
P 0.172 0.757 0.060 0.864 0.670 0.811
Haemoglobin o14gdl
 1 22 824 629 1412 2279 1491 3814
X14gdl
 1 13 1367 502 1764 1955 1193 3012
P 0.037 0.158 0.142 0.517 0.597 0.375
CALGB prognostic group Groups 1, 2 10 1247 562 1567 2218 1090 3265
Groups 3,4 17 820 662 1693 2241 1622 3485
Groups 5,6 8 1036 608 1353 2446 1113 4087
P 0.598 0.363 0.999 0.890 0.187 0.592
EORTC prognostic group Low risk 20 895 611 1448 2279 1440 3547
High risk 15 1157 608 1764 2092 1199 4018
P 0.463 0.534 0.217 0.714 0.841 0.790
IMIG nodal status N0, N1 8 1091 189 1353 1093 1086 3069
N2 5 1042 662 1727 3643 1852 6097
P 0.884 0.075 0.107 0.019 0.013 0.008
IMIG stage II 2 962 383 1345 1566 1317 2883
III 11 1043 625 1483 2847 1725 4677
IV 8 1000 409 1437 1923 1184 3207
P 0.840 0.689 0.755 0.173 0.797 0.353
The median densitometry value for each isoform is quoted. The Mann–Whitney U-test was used for the comparison of two groups and the Kruskal–Wallis Test for greater than
two groups. Total MMP activity equals the sum of pro- and active enzyme values. MMP-9¼gelatinase B; MMP-2¼gelatinase A; CALGB¼Cancer and Leukemia Group B;
EORTC¼European Organisation for Research and Treatment of Cancer; IMIG¼International Mesothelioma Interest Group.
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Figure 3 Scatterplot showing the relation between survival and total
MMP-2 activity (sum of pro-MMP-2 and active MMP-2 band arbitrary
densitometry units). There was a trend towards worse survival in patients
with increasing values (P¼0.08, Cox proportional hazards).
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cancer, the relations between MMP activities and tumour
progression remain unclear. Waas et al (2002) found no
association between MMP activity and nodal metastasis, but did
note significantly lower tumour extract MMP-2 activity in patients
with distant metastasis. Baker found that total MMP-2 and -9 levels
in colorectal tumour samples, as assessed by gelatinase activity
assays, correlated positively with Dukes’ stages (Baker and Leaper,
2002). Liabakk, however, demonstrated higher levels of MMP-9 in
Dukes’ stages A and C (Liabakk et al, 1996). Brown found that
active MMP-2 correlated with stage in NSCLC (Brown et al, 1993b)
but not breast cancer (Brown et al, 1993a). Pro-MMP-9, but neither
MMP-2 isoform, was associated with poor survival in both
univariate and multivariate analyses in ovarian cancer (Lengyel
et al, 2001). No relations were seen in bladder cancer (Papathoma
et al, 2000), hepatocellular carcinoma (Maatta et al, 2000) or soft-
tissue sarcomas (Maguire et al, 2000).
The numbers in our study are relatively small, particularly with
respect to those with an accurate pathological TNM stage. The
accuracy of radiological TNM staging in MM remains unclear and
therefore we made no attempt to assess the stage of patients who
did not undergo radical surgery and detailed pathological
assessment. Nonetheless, the positive correlation between MMP-2
activity and nodal status noted here is in keeping with a number of
studies in other tumours cited above. Similarly, although our
multivariate survival analyses may lack high statistical rigour, our
results are provocative and justify confirmatory studies in a larger
series of patients.
The regulation of MMP expression (Jones and Walker, 1997) in
MM remains to be characterised. Nonetheless, many growth
factors known to induce MMP expression are detectable in MM.
These include basic fibroblast growth factor (bFGF) (Kumar-Singh
et al, 1999), hepatocyte growth factor/scatter factor (Tolnay et al,
1998), vascular endothelial growth factor (VEGF) (Ohta et al,
1999), insulin-like growth factor (IGF)-1, tumour necrosis factor
(TNF), transforming growth factors-a and -b (Bielefeldt-Ohmann
et al, 1996) and interleukin-8 (Antony et al, 1996). The inter-
relation between these growth factors and MMP expression in MM
tumour samples needs to be investigated. Furthermore, gelatin
zymography does not discriminate between free MMPs and those
complexed with TIMPs, mRNA for which have been identified in
MM cells in vitro (Liu et al, 2001). Further study is required to
address the balance of MMPs with respect to TIMPs in MM tumour
samples.
The detection of active gelatinase isoforms in MM samples,
particularly MMP-2, is important and suggests that MMP
inhibitors may be therapeutic in this disease. Evidence to support
this contention comes from both experimental and clinical studies.
Inhibition of MMPs reduces tumour growth, invasion and
angiogenesis in vivo (Maekawa et al, 1999). Initial phase III trials
of MMP inhibitors in other solid tumours alone or in combination
with cytotoxic agents have overall been disappointing (Bissett et al,
2002; Bramhall et al, 2002a,b). Nonetheless, inhibition of MMP
activity, with synthetic MMP inhibitors (Drummond et al, 1999;
Steward, 1999) or with biological agents that downregulate the
synthesis and activation of the enzymes such as the selective COX-
2 inhibitors (Reich and Martin, 1996; Attiga et al, 2000; Pan et al,
2001; Abiru et al, 2002), deserves clinical investigation as a novel
approach to the management of MM.
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